Under the new collaboration, OpenFold will produce a fine-tuned version of its model that’s trained on AbbVie and Johnson & ...

In this week’s edition of InnovationRx, we look at the trend in fatal drug overdoses, 23andMe’s bankruptcy, the new CDC ...

Emergent BioSolutions struggles with declining revenues, rising competition, and weak growth prospects. Read why I rate EBS ...

In January, 2025, J&J’s nasal spray Spravato secured a label expansion from the FDA for use as a single agent in adults with ...

Tesla boss Elon Musk seems to be on a mission to conquer the world, and even Mars. But his odd-hour rants, alleged Nazi ...

If you've been HBO’s new season of White Lotus, then you've seen Parker Posey’s character Victoria Ratliff popping a steady ...

A month into his role as health and human services secretary, Robert F. Kennedy Jr.'s moves on vaccines have worried health ...

Celltrion has launched Steqeyma (ustekinumab-stba), its biosimilar of Stelara (ustekinumab), at list price at an 85% discount ...

Milestone Pharmaceuticals Inc. announced that the FDA has ... for its nasal spray CARDAMYST™ (etripamil), aimed at treating Paroxysmal Supraventricular Tachycardia (PSVT). If approved, Milestone ...

chronic rhinosinusitis with nasal polyps, immunoglobulin E-mediated (IgE) food allergy and chronic spontaneous urticaria. "We are proud to achieve the approval of the first biosimilar to ...

The FDA’s latest draft guidance on accelerated approval for new drugs, “Expedited Program for Serious Conditions—Accelerated Approval of Drugs and Biologics,” is a game-changer for biopharmaceutical ...

Johnson & Johnson announced new icotrokinra, JNJ-2113, data from its comprehensive Phase 3 clinical program and the start of the first-ever head-to-head study in plaque psoriasis, PsO, seeking to ...